nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—ALB—focal segmental glomerulosclerosis	0.618	1	CbGaD
Gliclazide—CYP2C19—Cyclosporine—focal segmental glomerulosclerosis	0.0624	0.546	CbGbCtD
Gliclazide—CYP2C9—Cyclosporine—focal segmental glomerulosclerosis	0.0519	0.454	CbGbCtD
Gliclazide—VEGFA—VEGFR1 specific signals—CD2AP—focal segmental glomerulosclerosis	0.0059	0.0477	CbGpPWpGaD
Gliclazide—ALB—Scavenging of heme from plasma—APOL1—focal segmental glomerulosclerosis	0.00571	0.0462	CbGpPWpGaD
Gliclazide—VEGFA—EPHA-mediated growth cone collapse—MYH10—focal segmental glomerulosclerosis	0.00568	0.0459	CbGpPWpGaD
Gliclazide—Hyperkeratosis—Cyclosporine—focal segmental glomerulosclerosis	0.00544	0.0378	CcSEcCtD
Gliclazide—Carcinoma—Cyclosporine—focal segmental glomerulosclerosis	0.00515	0.0357	CcSEcCtD
Gliclazide—Paresis—Cyclosporine—focal segmental glomerulosclerosis	0.00426	0.0296	CcSEcCtD
Gliclazide—VEGFA—Signaling events mediated by TCPTP—PIAS1—focal segmental glomerulosclerosis	0.00369	0.0298	CbGpPWpGaD
Gliclazide—VEGFA—Beta3 integrin cell surface interactions—COL4A4—focal segmental glomerulosclerosis	0.00348	0.0282	CbGpPWpGaD
Gliclazide—Pancreatitis acute—Cyclosporine—focal segmental glomerulosclerosis	0.00337	0.0234	CcSEcCtD
Gliclazide—Nephropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00327	0.0227	CcSEcCtD
Gliclazide—Bursitis—Cyclosporine—focal segmental glomerulosclerosis	0.00322	0.0223	CcSEcCtD
Gliclazide—VEGFA—Beta3 integrin cell surface interactions—COL4A1—focal segmental glomerulosclerosis	0.0032	0.0259	CbGpPWpGaD
Gliclazide—VEGFA—EPHA-mediated growth cone collapse—MYH9—focal segmental glomerulosclerosis	0.00311	0.0252	CbGpPWpGaD
Gliclazide—Hypertriglyceridaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00271	0.0188	CcSEcCtD
Gliclazide—VEGFA—Beta3 integrin cell surface interactions—COL4A3—focal segmental glomerulosclerosis	0.00271	0.0219	CbGpPWpGaD
Gliclazide—Cerebration impaired—Cyclosporine—focal segmental glomerulosclerosis	0.00265	0.0184	CcSEcCtD
Gliclazide—VEGFA—Integrins in angiogenesis—COL4A4—focal segmental glomerulosclerosis	0.00257	0.0207	CbGpPWpGaD
Gliclazide—VEGFA—S1P3 pathway—GNAQ—focal segmental glomerulosclerosis	0.00257	0.0207	CbGpPWpGaD
Gliclazide—VEGFA—Platelet degranulation—ACTN4—focal segmental glomerulosclerosis	0.00252	0.0204	CbGpPWpGaD
Gliclazide—VEGFA—EPH-Ephrin signaling—MYH10—focal segmental glomerulosclerosis	0.00252	0.0204	CbGpPWpGaD
Gliclazide—VEGFA—Beta1 integrin cell surface interactions—COL4A4—focal segmental glomerulosclerosis	0.00247	0.02	CbGpPWpGaD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—ACTN4—focal segmental glomerulosclerosis	0.0024	0.0194	CbGpPWpGaD
Gliclazide—Tooth disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0024	0.0166	CcSEcCtD
Gliclazide—Nail disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0024	0.0166	CcSEcCtD
Gliclazide—Blood triglycerides increased—Cyclosporine—focal segmental glomerulosclerosis	0.00237	0.0165	CcSEcCtD
Gliclazide—VEGFA—Integrins in angiogenesis—COL4A1—focal segmental glomerulosclerosis	0.00236	0.0191	CbGpPWpGaD
Gliclazide—Digestion impaired—Cyclosporine—focal segmental glomerulosclerosis	0.00233	0.0161	CcSEcCtD
Gliclazide—Menstrual disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00228	0.0158	CcSEcCtD
Gliclazide—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOL1—focal segmental glomerulosclerosis	0.00228	0.0184	CbGpPWpGaD
Gliclazide—VEGFA—Beta1 integrin cell surface interactions—COL4A1—focal segmental glomerulosclerosis	0.00227	0.0184	CbGpPWpGaD
Gliclazide—Hyperlipidaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00216	0.015	CcSEcCtD
Gliclazide—Cholestasis—Cyclosporine—focal segmental glomerulosclerosis	0.00205	0.0142	CcSEcCtD
Gliclazide—Fungal infection—Cyclosporine—focal segmental glomerulosclerosis	0.00201	0.014	CcSEcCtD
Gliclazide—Skin ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.002	0.0139	CcSEcCtD
Gliclazide—VEGFA—Integrins in angiogenesis—COL4A3—focal segmental glomerulosclerosis	0.00199	0.0161	CbGpPWpGaD
Gliclazide—VEGFA—Beta1 integrin cell surface interactions—COL4A3—focal segmental glomerulosclerosis	0.00192	0.0155	CbGpPWpGaD
Gliclazide—VEGFA—Alpha9 beta1 integrin signaling events—SPP1—focal segmental glomerulosclerosis	0.00183	0.0148	CbGpPWpGaD
Gliclazide—Neoplasm malignant—Cyclosporine—focal segmental glomerulosclerosis	0.00182	0.0126	CcSEcCtD
Gliclazide—Disturbance in attention—Cyclosporine—focal segmental glomerulosclerosis	0.0018	0.0125	CcSEcCtD
Gliclazide—Viral infection—Cyclosporine—focal segmental glomerulosclerosis	0.00172	0.012	CcSEcCtD
Gliclazide—Arthropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00171	0.0119	CcSEcCtD
Gliclazide—Nocturia—Cyclosporine—focal segmental glomerulosclerosis	0.00168	0.0116	CcSEcCtD
Gliclazide—Gout—Cyclosporine—focal segmental glomerulosclerosis	0.00167	0.0116	CcSEcCtD
Gliclazide—Cataract—Cyclosporine—focal segmental glomerulosclerosis	0.00163	0.0113	CcSEcCtD
Gliclazide—Hearing impaired—Cyclosporine—focal segmental glomerulosclerosis	0.00163	0.0113	CcSEcCtD
Gliclazide—VEGFA—Alpha9 beta1 integrin signaling events—FN1—focal segmental glomerulosclerosis	0.00153	0.0123	CbGpPWpGaD
Gliclazide—VEGFA—Alpha9 beta1 integrin signaling events—NOS2—focal segmental glomerulosclerosis	0.00151	0.0122	CbGpPWpGaD
Gliclazide—Blood urea increased—Cyclosporine—focal segmental glomerulosclerosis	0.00147	0.0102	CcSEcCtD
Gliclazide—Neuropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00146	0.0101	CcSEcCtD
Gliclazide—Coma—Cyclosporine—focal segmental glomerulosclerosis	0.00142	0.00986	CcSEcCtD
Gliclazide—Oesophagitis—Cyclosporine—focal segmental glomerulosclerosis	0.00142	0.00986	CcSEcCtD
Gliclazide—Urine output increased—Cyclosporine—focal segmental glomerulosclerosis	0.00141	0.00976	CcSEcCtD
Gliclazide—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.00141	0.00976	CcSEcCtD
Gliclazide—VEGFA—EPH-Ephrin signaling—MYH9—focal segmental glomerulosclerosis	0.00138	0.0112	CbGpPWpGaD
Gliclazide—Abnormal vision—Cyclosporine—focal segmental glomerulosclerosis	0.00136	0.00941	CcSEcCtD
Gliclazide—Mental disability—Cyclosporine—focal segmental glomerulosclerosis	0.00135	0.00937	CcSEcCtD
Gliclazide—Hepatic function abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00129	0.00897	CcSEcCtD
Gliclazide—Polyuria—Cyclosporine—focal segmental glomerulosclerosis	0.00129	0.00892	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.00128	0.0103	CbGpPWpGaD
Gliclazide—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.00127	0.00884	CcSEcCtD
Gliclazide—Deafness—Cyclosporine—focal segmental glomerulosclerosis	0.00126	0.00876	CcSEcCtD
Gliclazide—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.00126	0.00872	CcSEcCtD
Gliclazide—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.00126	0.00872	CcSEcCtD
Gliclazide—Injury—Cyclosporine—focal segmental glomerulosclerosis	0.00123	0.00853	CcSEcCtD
Gliclazide—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.0012	0.00834	CcSEcCtD
Gliclazide—Visual disturbance—Cyclosporine—focal segmental glomerulosclerosis	0.00119	0.00827	CcSEcCtD
Gliclazide—Renal impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00119	0.00823	CcSEcCtD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—LPL—focal segmental glomerulosclerosis	0.00119	0.00958	CbGpPWpGaD
Gliclazide—VEGFA—Beta3 integrin cell surface interactions—SPP1—focal segmental glomerulosclerosis	0.00119	0.00958	CbGpPWpGaD
Gliclazide—ALB—Binding and Uptake of Ligands by Scavenger Receptors—COL4A1—focal segmental glomerulosclerosis	0.00117	0.00949	CbGpPWpGaD
Gliclazide—Arthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00116	0.00806	CcSEcCtD
Gliclazide—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00116	0.00803	CcSEcCtD
Gliclazide—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.00116	0.00803	CcSEcCtD
Gliclazide—ABCC8—Regulation of insulin secretion—GNAQ—focal segmental glomerulosclerosis	0.00114	0.00923	CbGpPWpGaD
Gliclazide—Osteoarthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00113	0.00784	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—ACTN4—focal segmental glomerulosclerosis	0.00112	0.00905	CbGpPWpGaD
Gliclazide—KCNJ11—Regulation of insulin secretion—GNAQ—focal segmental glomerulosclerosis	0.00111	0.00895	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—COL4A4—focal segmental glomerulosclerosis	0.00106	0.00858	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.00106	0.00854	CbGpPWpGaD
Gliclazide—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.00103	0.00718	CcSEcCtD
Gliclazide—VEGFA—Angiogenesis—MMP9—focal segmental glomerulosclerosis	0.00101	0.00812	CbGpPWpGaD
Gliclazide—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.000999	0.00693	CcSEcCtD
Gliclazide—VEGFA—HIF-2-alpha transcription factor network—SERPINE1—focal segmental glomerulosclerosis	0.000993	0.00802	CbGpPWpGaD
Gliclazide—VEGFA—Beta3 integrin cell surface interactions—FN1—focal segmental glomerulosclerosis	0.000989	0.00799	CbGpPWpGaD
Gliclazide—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.000982	0.00682	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—COL4A1—focal segmental glomerulosclerosis	0.000975	0.00788	CbGpPWpGaD
Gliclazide—ALB—Lipoprotein metabolism—LIPC—focal segmental glomerulosclerosis	0.000965	0.0078	CbGpPWpGaD
Gliclazide—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.000938	0.00651	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—MYH10—focal segmental glomerulosclerosis	0.000936	0.00757	CbGpPWpGaD
Gliclazide—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000935	0.00649	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—AGTR1—focal segmental glomerulosclerosis	0.000935	0.00756	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—EDN1—focal segmental glomerulosclerosis	0.000915	0.0074	CbGpPWpGaD
Gliclazide—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000907	0.00629	CcSEcCtD
Gliclazide—ABCC8—Integration of energy metabolism—GNAQ—focal segmental glomerulosclerosis	0.000898	0.00726	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—ACTN4—focal segmental glomerulosclerosis	0.000891	0.0072	CbGpPWpGaD
Gliclazide—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.000888	0.00616	CcSEcCtD
Gliclazide—ABCC8—FOXA2 and FOXA3 transcription factor networks—ALB—focal segmental glomerulosclerosis	0.000883	0.00713	CbGpPWpGaD
Gliclazide—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00088	0.00611	CcSEcCtD
Gliclazide—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.000875	0.00607	CcSEcCtD
Gliclazide—VEGFA—Integrins in angiogenesis—SPP1—focal segmental glomerulosclerosis	0.000873	0.00705	CbGpPWpGaD
Gliclazide—KCNJ11—Integration of energy metabolism—GNAQ—focal segmental glomerulosclerosis	0.000871	0.00704	CbGpPWpGaD
Gliclazide—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.000868	0.00602	CcSEcCtD
Gliclazide—VEGFA—Endochondral Ossification—SPP1—focal segmental glomerulosclerosis	0.000862	0.00697	CbGpPWpGaD
Gliclazide—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.000858	0.00595	CcSEcCtD
Gliclazide—KCNJ11—FOXA2 and FOXA3 transcription factor networks—ALB—focal segmental glomerulosclerosis	0.000856	0.00692	CbGpPWpGaD
Gliclazide—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.000855	0.00594	CcSEcCtD
Gliclazide—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.000853	0.00592	CcSEcCtD
Gliclazide—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.000853	0.00592	CcSEcCtD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—ACTN4—focal segmental glomerulosclerosis	0.000849	0.00686	CbGpPWpGaD
Gliclazide—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.000848	0.00589	CcSEcCtD
Gliclazide—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.000846	0.00587	CcSEcCtD
Gliclazide—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000846	0.00587	CcSEcCtD
Gliclazide—VEGFA—Beta1 integrin cell surface interactions—SPP1—focal segmental glomerulosclerosis	0.000841	0.0068	CbGpPWpGaD
Gliclazide—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.000823	0.00571	CcSEcCtD
Gliclazide—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.000821	0.0057	CcSEcCtD
Gliclazide—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.000816	0.00567	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—CD40LG—focal segmental glomerulosclerosis	0.000784	0.00633	CbGpPWpGaD
Gliclazide—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.000783	0.00543	CcSEcCtD
Gliclazide—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000781	0.00542	CcSEcCtD
Gliclazide—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000777	0.00539	CcSEcCtD
Gliclazide—VEGFA—Glypican 1 network—TGFB1—focal segmental glomerulosclerosis	0.000777	0.00628	CbGpPWpGaD
Gliclazide—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.000775	0.00538	CcSEcCtD
Gliclazide—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.000753	0.00522	CcSEcCtD
Gliclazide—VEGFA—Integrins in angiogenesis—FN1—focal segmental glomerulosclerosis	0.000729	0.00589	CbGpPWpGaD
Gliclazide—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.000728	0.00505	CcSEcCtD
Gliclazide—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.000725	0.00503	CcSEcCtD
Gliclazide—VEGFA—Beta1 integrin cell surface interactions—FN1—focal segmental glomerulosclerosis	0.000702	0.00567	CbGpPWpGaD
Gliclazide—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.000701	0.00486	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.000698	0.00564	CbGpPWpGaD
Gliclazide—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.000698	0.00484	CcSEcCtD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—NOS2—focal segmental glomerulosclerosis	0.000694	0.00561	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—COL4A4—focal segmental glomerulosclerosis	0.000693	0.0056	CbGpPWpGaD
Gliclazide—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000684	0.00475	CcSEcCtD
Gliclazide—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00068	0.00472	CcSEcCtD
Gliclazide—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.00067	0.00465	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—MYH10—focal segmental glomerulosclerosis	0.000668	0.0054	CbGpPWpGaD
Gliclazide—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.000667	0.00463	CcSEcCtD
Gliclazide—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.00066	0.00458	CcSEcCtD
Gliclazide—ALB—Lipid and lipoprotein metabolism—LIPC—focal segmental glomerulosclerosis	0.000641	0.00518	CbGpPWpGaD
Gliclazide—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.000637	0.00442	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—COL4A1—focal segmental glomerulosclerosis	0.000636	0.00514	CbGpPWpGaD
Gliclazide—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000631	0.00438	CcSEcCtD
Gliclazide—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000628	0.00436	CcSEcCtD
Gliclazide—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.000625	0.00434	CcSEcCtD
Gliclazide—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.000621	0.00431	CcSEcCtD
Gliclazide—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.000613	0.00426	CcSEcCtD
Gliclazide—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000609	0.00422	CcSEcCtD
Gliclazide—VEGFA—Platelet degranulation—FN1—focal segmental glomerulosclerosis	0.000602	0.00486	CbGpPWpGaD
Gliclazide—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000593	0.00412	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—SERPINE1—focal segmental glomerulosclerosis	0.000591	0.00478	CbGpPWpGaD
Gliclazide—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.000589	0.00409	CcSEcCtD
Gliclazide—ALB—Lipoprotein metabolism—LPL—focal segmental glomerulosclerosis	0.000589	0.00476	CbGpPWpGaD
Gliclazide—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.000587	0.00407	CcSEcCtD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—SERPINE1—focal segmental glomerulosclerosis	0.000584	0.00472	CbGpPWpGaD
Gliclazide—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.000579	0.00402	CcSEcCtD
Gliclazide—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000579	0.00402	CcSEcCtD
Gliclazide—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000579	0.00402	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—ACTN4—focal segmental glomerulosclerosis	0.000577	0.00466	CbGpPWpGaD
Gliclazide—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.000577	0.004	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000575	0.00399	CcSEcCtD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—FN1—focal segmental glomerulosclerosis	0.000573	0.00463	CbGpPWpGaD
Gliclazide—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000572	0.00397	CcSEcCtD
Gliclazide—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.000566	0.00393	CcSEcCtD
Gliclazide—CYP2C19—Melatonin metabolism and effects—EDN1—focal segmental glomerulosclerosis	0.00056	0.00452	CbGpPWpGaD
Gliclazide—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.00056	0.00388	CcSEcCtD
Gliclazide—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000551	0.00383	CcSEcCtD
Gliclazide—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000544	0.00378	CcSEcCtD
Gliclazide—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000543	0.00377	CcSEcCtD
Gliclazide—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000539	0.00374	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—COL4A3—focal segmental glomerulosclerosis	0.000538	0.00435	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—TRPC6—focal segmental glomerulosclerosis	0.000537	0.00434	CbGpPWpGaD
Gliclazide—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.000536	0.00372	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—MYH9—focal segmental glomerulosclerosis	0.000513	0.00415	CbGpPWpGaD
Gliclazide—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000506	0.00351	CcSEcCtD
Gliclazide—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.000502	0.00348	CcSEcCtD
Gliclazide—VEGFA—Platelet degranulation—SERPINE1—focal segmental glomerulosclerosis	0.000501	0.00405	CbGpPWpGaD
Gliclazide—VEGFA—Platelet degranulation—ALB—focal segmental glomerulosclerosis	0.0005	0.00404	CbGpPWpGaD
Gliclazide—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000498	0.00346	CcSEcCtD
Gliclazide—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000495	0.00343	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—COL4A4—focal segmental glomerulosclerosis	0.000494	0.00399	CbGpPWpGaD
Gliclazide—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.000493	0.00342	CcSEcCtD
Gliclazide—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000488	0.00339	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000479	0.00333	CcSEcCtD
Gliclazide—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000478	0.00332	CcSEcCtD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—SERPINE1—focal segmental glomerulosclerosis	0.000477	0.00386	CbGpPWpGaD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—ALB—focal segmental glomerulosclerosis	0.000476	0.00385	CbGpPWpGaD
Gliclazide—VEGFA—Differentiation Pathway—TGFB1—focal segmental glomerulosclerosis	0.000476	0.00384	CbGpPWpGaD
Gliclazide—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000475	0.00329	CcSEcCtD
Gliclazide—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000475	0.00329	CcSEcCtD
Gliclazide—VEGFA—Endochondral Ossification—MMP9—focal segmental glomerulosclerosis	0.000459	0.00371	CbGpPWpGaD
Gliclazide—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000457	0.00317	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—COL4A1—focal segmental glomerulosclerosis	0.000454	0.00367	CbGpPWpGaD
Gliclazide—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000454	0.00315	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—GNAQ—focal segmental glomerulosclerosis	0.000449	0.00363	CbGpPWpGaD
Gliclazide—VEGFA—EPH-Ephrin signaling—MMP2—focal segmental glomerulosclerosis	0.000449	0.00363	CbGpPWpGaD
Gliclazide—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.000441	0.00306	CcSEcCtD
Gliclazide—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000439	0.00304	CcSEcCtD
Gliclazide—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000439	0.00304	CcSEcCtD
Gliclazide—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000409	0.00284	CcSEcCtD
Gliclazide—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000398	0.00276	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—TRPC6—focal segmental glomerulosclerosis	0.000395	0.0032	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—ACTN4—focal segmental glomerulosclerosis	0.000395	0.00319	CbGpPWpGaD
Gliclazide—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000393	0.00272	CcSEcCtD
Gliclazide—ALB—Lipid and lipoprotein metabolism—LPL—focal segmental glomerulosclerosis	0.000391	0.00316	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—ANGPT2—focal segmental glomerulosclerosis	0.000386	0.00312	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—COL4A3—focal segmental glomerulosclerosis	0.000384	0.0031	CbGpPWpGaD
Gliclazide—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00038	0.00264	CcSEcCtD
Gliclazide—VEGFA—Endochondral Ossification—TGFB1—focal segmental glomerulosclerosis	0.000378	0.00305	CbGpPWpGaD
Gliclazide—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000367	0.00255	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—MYH9—focal segmental glomerulosclerosis	0.000366	0.00296	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—SPP1—focal segmental glomerulosclerosis	0.000361	0.00292	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.000353	0.00285	CbGpPWpGaD
Gliclazide—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000353	0.00245	CcSEcCtD
Gliclazide—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.00035	0.00243	CcSEcCtD
Gliclazide—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00035	0.00243	CcSEcCtD
Gliclazide—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000348	0.00241	CcSEcCtD
Gliclazide—VEGFA—EPH-Ephrin signaling—MMP9—focal segmental glomerulosclerosis	0.000337	0.00272	CbGpPWpGaD
Gliclazide—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00033	0.00229	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—TGFB1—focal segmental glomerulosclerosis	0.000319	0.00258	CbGpPWpGaD
Gliclazide—VEGFA—Platelet degranulation—TGFB1—focal segmental glomerulosclerosis	0.000316	0.00255	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—FN1—focal segmental glomerulosclerosis	0.000301	0.00243	CbGpPWpGaD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—TGFB1—focal segmental glomerulosclerosis	0.000301	0.00243	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TRPC6—focal segmental glomerulosclerosis	0.000282	0.00228	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TRPC6—focal segmental glomerulosclerosis	0.000277	0.00224	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	0.000267	0.00216	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000262	0.00212	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—SERPINE1—focal segmental glomerulosclerosis	0.000253	0.00205	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—GNAQ—focal segmental glomerulosclerosis	0.000231	0.00187	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	0.000222	0.0018	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—ALB—focal segmental glomerulosclerosis	0.000222	0.00179	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—FN1—focal segmental glomerulosclerosis	0.000212	0.00172	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—SERPINE1—focal segmental glomerulosclerosis	0.000206	0.00167	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—ACTN4—focal segmental glomerulosclerosis	0.000204	0.00165	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—FN1—focal segmental glomerulosclerosis	0.000202	0.00164	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—TRPC6—focal segmental glomerulosclerosis	0.00019	0.00153	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—LPL—focal segmental glomerulosclerosis	0.000177	0.00143	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—SERPINE1—focal segmental glomerulosclerosis	0.000177	0.00143	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—SERPINE1—focal segmental glomerulosclerosis	0.000168	0.00136	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—MMP2—focal segmental glomerulosclerosis	0.000167	0.00135	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000164	0.00133	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—SERPINE1—focal segmental glomerulosclerosis	0.000164	0.00132	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—GNAQ—focal segmental glomerulosclerosis	0.000158	0.00128	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	0.000158	0.00127	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000151	0.00122	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	0.00014	0.00113	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—FN1—focal segmental glomerulosclerosis	0.000138	0.00111	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—ANGPT2—focal segmental glomerulosclerosis	0.000136	0.0011	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—NOS2—focal segmental glomerulosclerosis	0.000136	0.0011	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000128	0.00103	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000127	0.00102	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—MMP9—focal segmental glomerulosclerosis	0.000125	0.00101	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000123	0.000992	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MMP2—focal segmental glomerulosclerosis	0.000119	0.000961	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	0.000115	0.000925	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—ALB—focal segmental glomerulosclerosis	0.000114	0.000923	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—TGFB1—focal segmental glomerulosclerosis	0.000112	0.000902	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000111	0.000901	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	0.000108	0.000875	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000108	0.000873	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—focal segmental glomerulosclerosis	0.000106	0.000859	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.000103	0.00083	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GNAQ—focal segmental glomerulosclerosis	9.96e-05	0.000805	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TRPC6—focal segmental glomerulosclerosis	9.77e-05	0.000789	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	9.42e-05	0.000761	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	9.39e-05	0.000758	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	9.33e-05	0.000754	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	9.17e-05	0.000741	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MMP9—focal segmental glomerulosclerosis	8.94e-05	0.000722	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	8.46e-05	0.000683	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	8.23e-05	0.000665	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—GNAQ—focal segmental glomerulosclerosis	8.17e-05	0.00066	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	8.07e-05	0.000652	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	7.85e-05	0.000634	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	7.84e-05	0.000633	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—LPL—focal segmental glomerulosclerosis	7.73e-05	0.000624	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	7.5e-05	0.000606	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—LPL—focal segmental glomerulosclerosis	7.49e-05	0.000605	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	7.37e-05	0.000595	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	7.24e-05	0.000585	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TGFB1—focal segmental glomerulosclerosis	7.23e-05	0.000584	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	7.18e-05	0.00058	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AGT—focal segmental glomerulosclerosis	6.61e-05	0.000534	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	6.61e-05	0.000534	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AGT—focal segmental glomerulosclerosis	6.41e-05	0.000518	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	6.08e-05	0.000492	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—LPL—focal segmental glomerulosclerosis	5.9e-05	0.000477	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	5.59e-05	0.000452	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	5.59e-05	0.000452	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ALB—focal segmental glomerulosclerosis	5.07e-05	0.00041	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AGT—focal segmental glomerulosclerosis	5.05e-05	0.000408	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	5.02e-05	0.000406	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	4.95e-05	0.0004	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ALB—focal segmental glomerulosclerosis	4.92e-05	0.000397	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—FN1—focal segmental glomerulosclerosis	4.86e-05	0.000392	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NOS2—focal segmental glomerulosclerosis	4.8e-05	0.000388	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	4.79e-05	0.000387	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.67e-05	0.000377	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	4.58e-05	0.00037	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	4.3e-05	0.000347	CbGpPWpGaD
Gliclazide—ALB—Metabolism—LIPC—focal segmental glomerulosclerosis	4.08e-05	0.00033	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	4.04e-05	0.000327	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	3.92e-05	0.000316	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.88e-05	0.000314	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—LIPC—focal segmental glomerulosclerosis	3.66e-05	0.000296	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CTGF—focal segmental glomerulosclerosis	3.59e-05	0.00029	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—LIPC—focal segmental glomerulosclerosis	3.34e-05	0.00027	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.31e-05	0.000268	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	3.3e-05	0.000266	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CTGF—focal segmental glomerulosclerosis	3.23e-05	0.000261	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	3.01e-05	0.000243	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.97e-05	0.00024	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.97e-05	0.00024	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CTGF—focal segmental glomerulosclerosis	2.94e-05	0.000238	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.71e-05	0.000219	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TGFB1—focal segmental glomerulosclerosis	2.55e-05	0.000206	CbGpPWpGaD
Gliclazide—ALB—Metabolism—LPL—focal segmental glomerulosclerosis	2.49e-05	0.000201	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.45e-05	0.000198	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—LPL—focal segmental glomerulosclerosis	2.24e-05	0.000181	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AGT—focal segmental glomerulosclerosis	2.13e-05	0.000172	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—LPL—focal segmental glomerulosclerosis	2.04e-05	0.000165	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AGT—focal segmental glomerulosclerosis	1.91e-05	0.000155	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AGT—focal segmental glomerulosclerosis	1.74e-05	0.000141	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALB—focal segmental glomerulosclerosis	1.47e-05	0.000119	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALB—focal segmental glomerulosclerosis	1.34e-05	0.000108	CbGpPWpGaD
